Robert L. Hudkins

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

Arup K. Ghose, Torsten Herbertz, Robert L. Hudkins et al. · ACS Chemical Neuroscience · 2011 · 437 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Bruce Ruggeri, Diane E. Gingrich, Thelma S. Angeles et al. · PubMed · 2003 · 124 citations

Medicine, Oncology, Pharmacology +15

Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives

Masami Kaneko, Yutaka Saito, Hiromitsu Saito et al. · Journal of Medicinal Chemistry · 1997 · 120 citations · Full text

Life Sciences, Neurobiology, Neuroscience +15

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

Sheila Miknyoczki, Hong Chang, Jennifer V. Grobelny et al. · Molecular Cancer Therapeutics · 2007 · 112 citations

Medicine, Oncology, Pharmacology +15

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

Weihua Wan, Mark S. Albom, Lihui Lü et al. · Blood · 2005 · 105 citations

Veterinary Medicine, Cell Biology, Oncology +11